Search the site

An innovative response-adaptive approach to driving improvements in health outcomes, applied to cystic fibrosis.

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

18 months of age infants receiving 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine will have higher antibody levels

This manuscript will give a brief overview of clinical trial design including the strengths and limitations of various approaches

Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort

Aboriginal children are at greater risk of rotavirus disease than non-Aboriginal children and delayed vaccine receipt is substantially higher

Professor Tom Snelling

Head, Infectious Disease Implementation Research

Dr Ruth Thornton

Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG)